Mater Research Institute
Centre of Research Excellence in Stillbirth
Professor Vicki Flenady – Program summary
Professor Vicki Flenady is a Founding Member and Secretary of the Australian and New Zealand Stillbirth Alliance (ANZSA) and the current Secretary of the Perinatal Society of Australia and New Zealand Stillbirth and Neonatal Death Alliance (PSANZ-SANDA), and Convenor of the PSANZ Perinatal Mortality Group (PSANZ PMG) and Chairs the PSANZ IMPACT Network.
Professor Vicki Flenady is also the Director of the Centre of Research Excellence (CRE) in Stillbirth, a new initiative funded by the National Health and Medical Research Council in late 2016, and is administered by the Mater Research Institute – University of Queensland (MRI-UQ). The CRE in stillbirth is focused on the prevention of stillbirth and the optimisation of care for families who experience stillbirth with the aim of improving health outcomes for mothers and newborns more broadly, with a particular focus in Australia and New Zealand.
The CRE in stillbirth is a national collaboration involving clinicians, researchers, professional colleges, policy makers and parents to generate new knowledge about causes and prediction of stillbirth, as well as novel interventions for implementation of best practice in stillbirth prevention and care after stillbirth.
One of the projects that Professor Vicki Flenady, and Dr Glenn Gardener, the Director, Center for Maternal Fetal Medicine at Mater Mothers’ Hospital, are working on is a project called ‘My Baby’s Movements’. The goal of the project is to develop an app with the aim to enhance the prediction and appropriate management of at-risk pregnancies, whilst also collecting information about the occurrence of stillbirths across Australia and New Zealand.
While most decreases in movement in the womb are nothing to be concerned about, it can be an early sign that a baby may be experiencing some trouble. The app is designed to help monitor movements throughout a pregnancy.
This particular study is currently underway and will be conducted across 27 hospitals in Australia and New Zealand in total